Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Podcast with Prof. Dr. Radford about improved overall survival with first-line brentuximab vedotin plus
chemotherapy in patients with stage III/IV classical Hodgkin lymphoma
2. Sustained clinical benefit with sutimlimab in cold agglutinin disease patients with a history of red blood
cell transfusion
3. Axicabtagene ciloleucel demonstrates superiority over second-line standard of care in patients
≥ 65 years with R/R LBCL
4. Combination of ibrutinib plus venetoclax results in a high rate of MRD-negativity in previously untreated CLL
5. Ibrutinib plus bendamustine-rituximab for treatment naïve mantle-cell lymphoma
![Nplate Amgen Leaderboard banner EHA nieuwsbrief van 14juni22 en 16juni22](/images/EHA2022/Nplate_Amgen_Leaderboard_banner_EHA_nieuwsbrief_van_14juni22_en_16juni22.jpg)
![REBLOZYL BMS Halfway Banner DAY2 1062x138 BJH EHS Nieuwsbrief 16jun22](/images/EHA2022/REBLOZYL_BMS_Halfway_Banner_DAY2_1062x138_BJH_EHS_Nieuwsbrief_16jun22.jpg)
![Banner Calquence 700 finale versie](/images/EHA2022/Banner_Calquence-700-finale-versie.jpg)